FR3072973B1 - Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires - Google Patents

Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires Download PDF

Info

Publication number
FR3072973B1
FR3072973B1 FR1760110A FR1760110A FR3072973B1 FR 3072973 B1 FR3072973 B1 FR 3072973B1 FR 1760110 A FR1760110 A FR 1760110A FR 1760110 A FR1760110 A FR 1760110A FR 3072973 B1 FR3072973 B1 FR 3072973B1
Authority
FR
France
Prior art keywords
pseudo
immune dysfunction
viral particles
particles useful
treating immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1760110A
Other languages
English (en)
Other versions
FR3072973A1 (fr
Inventor
Bertrand Bellier
David Klatzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie Paris 6
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Universite Pierre et Marie Curie Paris 6
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1760110A priority Critical patent/FR3072973B1/fr
Application filed by Universite Pierre et Marie Curie Paris 6, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Universite Pierre et Marie Curie Paris 6
Priority to US16/759,125 priority patent/US11306294B2/en
Priority to PCT/FR2018/052676 priority patent/WO2019081873A1/fr
Priority to CA3078717A priority patent/CA3078717A1/fr
Priority to EP18804370.7A priority patent/EP3700555A1/fr
Priority to PCT/FR2018/052674 priority patent/WO2019081872A1/fr
Priority to EP18804369.9A priority patent/EP3700554A1/fr
Priority to US16/759,591 priority patent/US20210299195A1/en
Publication of FR3072973A1 publication Critical patent/FR3072973A1/fr
Application granted granted Critical
Publication of FR3072973B1 publication Critical patent/FR3072973B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une particule pseudovirale comprenant un antigène et une molécule immunorégulatrice exposée à sa surface. L'invention concerne également l'utilisation de la dite particule dans le traitement d'un dysfonctionnement immunitaire.
FR1760110A 2017-10-26 2017-10-26 Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires Active FR3072973B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR1760110A FR3072973B1 (fr) 2017-10-26 2017-10-26 Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires
PCT/FR2018/052676 WO2019081873A1 (fr) 2017-10-26 2018-10-26 Particules pseudo-virales utiles pour traiter des maladies auto-immunes
CA3078717A CA3078717A1 (fr) 2017-10-26 2018-10-26 Particules pseudo-virales utiles pour traiter des maladies auto-immunes
EP18804370.7A EP3700555A1 (fr) 2017-10-26 2018-10-26 Particules pseudo-virales utiles pour traiter des maladies auto-immunes
US16/759,125 US11306294B2 (en) 2017-10-26 2018-10-26 Virus-like particles which can be used in the treatment of autoimmune diseases
PCT/FR2018/052674 WO2019081872A1 (fr) 2017-10-26 2018-10-26 Particules pseudo-virales utiles pour traiter des allergies
EP18804369.9A EP3700554A1 (fr) 2017-10-26 2018-10-26 Particules pseudo-virales utiles pour traiter des allergies
US16/759,591 US20210299195A1 (en) 2017-10-26 2018-10-28 Virus-like particles which can be used in the treatment of allergies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1760110 2017-10-26
FR1760110A FR3072973B1 (fr) 2017-10-26 2017-10-26 Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires

Publications (2)

Publication Number Publication Date
FR3072973A1 FR3072973A1 (fr) 2019-05-03
FR3072973B1 true FR3072973B1 (fr) 2022-02-11

Family

ID=61132564

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1760110A Active FR3072973B1 (fr) 2017-10-26 2017-10-26 Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires

Country Status (5)

Country Link
US (2) US11306294B2 (fr)
EP (2) EP3700555A1 (fr)
CA (1) CA3078717A1 (fr)
FR (1) FR3072973B1 (fr)
WO (2) WO2019081873A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202313668A (zh) * 2021-05-20 2023-04-01 美商阿徹羅伊斯生物製藥公司 免疫檢查點多價粒子組合物及其使用方法
WO2022246041A2 (fr) * 2021-05-20 2022-11-24 Achelois Biopharma, Inc. Compositions et procédés pour un affichage de surface multivalent sur des particules enveloppées
WO2023039242A2 (fr) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Compositions de particules d'interféron multivalentes et procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (fr) 2000-10-26 2002-05-02 Genopoietic Virus synthétiques et leurs utilisations
EP2572734B1 (fr) * 2006-10-31 2016-04-06 East Carolina University Protéines de fusion à base de cytokine pour le traitement des troubles immunitaires
CN101486997A (zh) * 2009-02-11 2009-07-22 扬州大学 鸡痘病毒rFPV-AIH5/IL2及其构建方法和应用
JP5650212B2 (ja) * 2009-07-10 2015-01-07 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者を選択するためのバイオマーカーおよび関連方法
CA2975432A1 (fr) * 2015-02-13 2016-08-18 Transgene Sa Vaccin immunotherapeutique et therapie combinee a base d'anticorps

Also Published As

Publication number Publication date
WO2019081872A1 (fr) 2019-05-02
CA3078717A1 (fr) 2019-05-02
WO2019081873A1 (fr) 2019-05-02
FR3072973A1 (fr) 2019-05-03
EP3700555A1 (fr) 2020-09-02
US20200347363A1 (en) 2020-11-05
US11306294B2 (en) 2022-04-19
US20210299195A1 (en) 2021-09-30
EP3700554A1 (fr) 2020-09-02

Similar Documents

Publication Publication Date Title
MA44546A1 (fr) Virus adéno-associés variants et procédés d'utilisation
MA41013B1 (fr) Compositions comprenant des souches bactériennes
FR3072973B1 (fr) Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires
MA40035A (fr) Molécules d'anticorps de pd-l1 et leurs utilisations
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MX2019003768A (es) Moleculas de enlace especificas de hpv.
MX2018000999A (es) Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico.
WO2019224716A8 (fr) Anticorps spécifiques de gucy2c et leurs utilisations
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
FR3052993B1 (fr) Particule abrasive frittee a base d'oxydes presents dans la bauxite
MA51630A (fr) Utilisation de virus oncolytiques, seuls ou en combinaison avec un inhibiteur de point de contrôle immunitaire, pour le traitement du cancer
MX2016000381A (es) Particula tipo virus que comprende antigeno de muerte celular programada 1 o antigeno de ligando de muerte celular programada 1.
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
SA521421969B1 (ar) مكابس لاستخدامها فى أجهزة تبادل الموائع وأجهزة و أنظمة وطرق متعلقة بها
AR110762A1 (es) FORMULACIÓN QUE COMPRENDE ANTICUERPOS ANTI-FXIa
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
MA49373B1 (fr) Compositions comprenant des souches bactériennes
FR3044655B1 (fr) Procede de traitement d'effluent aqueux
FR3039434B1 (fr) Dispositif de collecte de particules contenues dans un aerosol, muni d'electrometres pour determiner la concentration et la granulometrie des nanoparticules
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA52811A (fr) Procédés d'utilisation de cd24 pour la prévention et le traitement d'une rechute de la leucémie
MA42006A1 (fr) Molécules hybrides
FR3029802B1 (fr) Dispositif permettant de limiter l'entrainement de particules solides en sortie d'un lit fluidise triphasique

Legal Events

Date Code Title Description
PLSC Publication of the preliminary search report

Effective date: 20190503

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7